Dose escalation offers no survival benefits but increases grade ≥ 3 toxicity compared with standard radiation in patients ...

Dr. Nataliya Uboha sat down to discuss the early warning signs of esophageal cancer, as well as important key takeaways for ...

The results of these trials could cement ICI-based immunotherapy as the new standard systemic treatment option for esophageal cancer.

While immunotherapy has improved outcomes in advanced esophageal cancer, its superiority over neoadjuvant chemoradiotherapy remains uncertain. This study included 1428 patients with locally ...

Zaidi said the five-year survival rate for patients with advanced esophageal cancer is typically less than 20%. With the experimental doublet immunotherapy drug combination, data show a promising ...

Because the five-year relative survival rate for people with esophageal cancer is approximately 22%, this makes early ...

McNamara's doctors unanimously recommended immunotherapy following his initial treatment ... Beating the odds: NJ man had 5% ...

I have cancer of the esophagus. It was a surprise because, except for some intermittent abdominal aches and pains, I had no symptoms. I'm going to undergo chemotherapy and immunotherapy right away.

“Esophageal cancer is an aggressive cancer, but treatments are always improving,” said Zeng. “For example, immunotherapy after chemoradiation has shown promise, and new treatments are being developed.